Search
Search
Close this search box.

SPONSORED: Tackling misinformation in the cannabis industry

Where to begin? With a prime example from the legal adult-use industry.

Do you prefer indica or sativa?

In cannabis retail stores across Canada and dispensaries in the US, products are typically categorised into indica-dominant, sativa-dominant or hybrid. Cannabis consultants – or budtenders – will advise consumers to expect an indica-dominant product, to produce a sedating effect, possibly even leading to ‘couch-lock’ and therefore best consumed in the evening. Indica = In da couch.

A sativa-dominant high is likely to be more energising or alerting and better suited for daytime consumption. With a hybrid, you can expect a combination of effects; depending on the ratio of indica to sativa – whatever that means!

The problem? It’s outdated nonsense.

I know this all too well as I was responsible for teaching it to retail staff in cannabis stores across British Columbia, believing it to be world class cannabis education. The truth is indica and sativa are terms used to describe the morphology of the plant and have no bearing on the expected effects on the consumer. The cannabinoid and terpene profiles of a particular chemovar of cannabis are a better indicator of gauging expected effects.

To add to that, everyone’s endocannabinoid system is unique. Cannabis affects us all differently and there is a need for cautious, personal experimentation, to find a product that works for your desired effect. We also have to consider a consumer’s mindset and setting prior to consumption, as it will also play an important role in their overall cannabis experience; especially to a newbie.

So, why do cannabis retailers continue to sell cannabis in these categories? Because it’s easy! Sativa & indica are simple terms to understand. It makes life easy for the budtender, the consumer and the producers marketing the products. As straightforward as it is to understand, it does little to help consumers to find the right product for them. We are sacrificing a more complicated truth in place of unfounded ease at the expense of the consumer.

What about the CBD industry?

Unfortunately, we see the same issues arise in the CBD industry which is awash with misinformation. Let’s dive into some examples.

Almost every website mentioning CBD will tell you that it is a ‘non-psychoactive’ compound. But, according to Dr. Ethan Russo, this is an inaccurate term, given its prominent pharmacological benefits on anxiety, schizophrenia, addiction, and possibly even depression. More accurately, we should be describing CBD as ‘non-intoxicating’.1

Am I being too pedantic here? Possibly. But if you’re not onboard with giving out correct information to your consumers, you’re part of the problem.

In the UK, it is widely believed that the limit of THC in legal CBD products is 0.2%, but this is also a common misconception. The 0.2% THC threshold refers to various rules in relation to cultivation and import of hemp. Under the Misuse of Drugs Regulations 2001, ‘exempt product’ status allows for the presence of no more than 1mg of THC in any given CBD product – although this now appears to be under review.

Add to the above the many unsubstantiated medical claims; CBD being hailed as a cure all and bogus products like CBD pillows, being sold to vulnerable people genuinely seeking relief from CBD, and it’s not a good look for the industry.

These examples are by no means an exhaustive list, but they are an indication that we as an industry need to do better, and to consistently give out the most up to date information to consumers. The cannabis industry is evolving at a fierce pace, and we have only scratched the surface on what we know about this powerful plant.

For the industry to progress in a better way, we need to be agile in our knowledge and education for the benefit of the consumer. Whether you’re involved in the medical, wellness or recreational side of the cannabis industry, the focus should always be on the end user experience.

Sativa Learning was created with the aims of providing the most up to date and accurate cannabis training and education available. Our CBD Industry Professional course has been developed by industry experts and includes a legal module which is reviewed and approved every quarter by Mackrell Solicitors, ensuring you receive the most current knowledge available.

We’re accredited by the CPD certification service to guarantee the content has been created to the highest standards of further learning. We are committed to providing cannabis organisations, entrepreneurs, jobseekers, academics, and medical professionals with the tools needed to cultivate a career in the cannabis industry.

As the cannabis industry grows worldwide, the gap in cannabis knowledge grows with it. We are here to bridge that gap.

Enrol in your next CPD accredited, CBD course today; or get in touch with us for more information.

🔒 Risk Management Report • Produced in partnership with RELM
Prohibition Partners RELM
📊 New Report Available Now

Relm Risk Briefing: Cannabis 2026

The global cannabis sector has moved from experiment to enterprise. This comprehensive risk briefing examines how regulation, insurance, and operational practices intersect across the international supply chain, drawing on insights from RELM—the only insurer entirely dedicated to the cannabis industry.

What's covered

  • 🌱 Cultivation risk management — biological contamination, environmental instability, and security protocols
  • ⚗️ Manufacturing & extraction — GMP standards, in-house testing, and quality control measures
  • 🔬 Testing & compliance — rigorous protocols ensuring product safety and regulatory adherence
  • 📦 Distribution & logistics — GDP-aligned transport, route monitoring, and cargo insurance
Key focus areas
Cultivation Manufacturing Testing & QC Packaging Distribution Retail & Pharmacy
100% free • Comprehensive risk analysis

Key insights

Industry Maturity Cannabis has evolved from patchwork markets to international enterprise, with risk management now the measure of long-term stability.
Cultivation Challenges Operators addressing biological contamination through controlled-environment agriculture, tissue culture, and IPM protocols.
Quality Control GMP adherence, in-house testing, and selective supplier relationships emerging as critical control points.
Supply Chain Security GDP-aligned transport, route monitoring, and comprehensive insurance remain essential safeguards.
Market Access Initiatives stabilizing domestic supply and expanding pharmacy training improving patient and consumer access.
Produced by Prohibition Partners in collaboration with RELM—the only insurer dedicated to emerging industries like cannabis.
Partnership
Produced by Prohibition Partners in collaboration with RELM

Related Posts

Related Posts

CONNECT

Related Posts

Related Posts

Recent Posts

Related Posts

Subscribe to our mailing list to receives daily updates!

We won’t spam you

Categories

Browse by Tags

CATEGORIES

EDITION

BUSINESS OF CANNABIS

© 2023 Prohibition Holdings Ltd. All Rights Reserved.

EDITION

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?